Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

7.900 +0.190 (+2.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,562,392
Open 7.800
Bid (Size) 7.310 (1)
Ask (Size) 8.220 (2)
Prev. Close 7.710
Today's Range 7.540 - 7.920
52wk Range 6.200 - 43.40
Shares Outstanding 142,227,952
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2... 
Via Benzinga

Performance

YTD
-72.66%
-72.66%
1 Month
-15.42%
-15.42%
3 Month
-41.87%
-41.87%
6 Month
-70.02%
-70.02%
1 Year
-78.42%
-78.42%

More News

Read More
Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO
Via Benzinga
Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues
Via Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Via Benzinga
Unusual Options Activity Insight: Adaptive Biotechnologies
Via Benzinga
Recap: Adaptive Biotechnologies Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
Earnings Scheduled For February 15, 2022
Via Benzinga
12 Publicly Traded Companies On Fast Company's 'Next Big Things In Tech' List
Via Benzinga
Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought
Via The Motley Fool
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Via Benzinga
Adaptive Biotechnologies Corporation (ADPT) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Via Benzinga
Topics Retirement
Exposures Pension
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
Return on Capital Employed Insights for Adaptive Biotechnologies
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Via Benzinga
Adaptive Biotechnologies Corporation (ADPT) Q2 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
This Explosive Biotech Is Taking On a Huge New Market
Via The Motley Fool
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.